1. Home
  2. CVKD vs ONCO Comparison

CVKD vs ONCO Comparison

Compare CVKD & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

N/A

Current Price

$1.71

Market Cap

3.4M

Sector

Health Care

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

N/A

Current Price

$3.15

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CVKD
ONCO
Founded
2022
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4M
3.0M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
CVKD
ONCO
Price
$1.71
$3.15
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $14.00
N/A
AVG Volume (30 Days)
103.3K
★ 2.6M
Earning Date
11-16-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 23.94
22.80
EPS
★ N/A
N/A
Revenue
N/A
★ $815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.82
$0.09
52 Week High
$12.50
$644.00

Technical Indicators

Market Signals
Indicator
CVKD
ONCO
Relative Strength Index (RSI) 66.44 58.90
Support Level $0.88 $0.56
Resistance Level $2.23 $7.82
Average True Range (ATR) 0.21 0.67
MACD 0.07 0.06
Stochastic Oscillator 78.44 36.87

Price Performance

Historical Comparison
CVKD
ONCO

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: